Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

ABSTRACT:

Unlabelled

The goals of therapy in patients with polycythemia vera (PV) are to improve disease-related symptoms, prevent the incidence or recurrence of thrombosis, and possibly delay or prevent the transformation into myelofibrosis or acute myeloid leukemia (AML). Cytoreductive therapies have been used in older patients and those with a history of thrombosis to achieve these goals. Hydroxyurea (HU) remains the first-line cytoreductive choice; however, up to one in four patients treated with HU over time will develop resistance or intolerance to HU. More importantly, patients who fail HU have a 5.6-fold increase in mortality and a 6.8-fold increase risk of transformation to myelofibrosis or AML; therefore, alternative therapies are needed for these patients. Interferon-α has been us

SUBMITTER: Nazha A 

PROVIDER: S-EPMC4828120 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature